BioTuesdays

AGP starts Trulieve Cannabis at buy; PT $40 (Canadian)

Alliance Global Partners launched coverage of Trulieve Cannabis (CSE:TRUL) with a “buy” rating and $40 (Canadian) price target. The stock was quoted at $23.74 in afternoon trading on Sept. 25. “We view Trulieve as a...

AGP starts Columbia Care at buy; PT $8 (Canadian)

Alliance Global Partners initiated coverage of Columbia Care (CSE:CCHW) with a “buy” rating and price target of $8 (Canadian). The stock was quoted at $4.41 in afternoon trading on Sept. 25. Columbia Care engages in...

Maxim starts Monopar Therapeutics at buy; PT $11

Maxim Group launched coverage of Monopar Therapeutics (NASDAQ:MNPR) with a “buy” rating and a 12-month price target of $11. The stock closed at $4.98 on Sept. 24. Monopar is focused on developing therapies for cancer...

BTIG starts MediWound at buy; PT $6

BTIG initiated coverage of MediWound (NASDAQ:MDWD) with a “buy” rating and $6 price target. The stock closed at $3.58 on Sept. 22. MediWound has developed proteolytic enzyme technology targeting severe burns, chronic...

OSE Immunotherapeutics

HCW ups OSE Immunotherapeutics PT to €10 from €7

H.C. Wainwright raised its price target for OSE Immunotherapeutics (NXT PA:OSE) to €10 from €7, citing strong results in PD-1 refractory non-small cell lung cancer (NSCLC) from the first 100-patient cohort of the Phase...

WB starts Aravive at OP

William Blair launched coverage of Aravive (NASDAQ:ARAV) with an “outperform” rating, saying that an “appreciable market disconnect exists between lead asset AVB-500’s potential to emerge as a differentiated therapeutic...

Medicenna Therapeutics

HCW starts Medicenna Therapeutics at buy; PT $8

H.C. Wainwright initiated coverage of Medicenna Therapeutics (NASDAQ:MDNA) with a “buy” rating and price target of $8. The stock closed at $3.88 on Sept. 8. Medicenna is an immuno-oncology company developing therapies...

Cowen starts DermTech at OP; PT $20

Cowen launched coverage of DermTech (NASDAQ:DMTK) with an “outperform” rating and $20 price target. The stock closed at $10.65 on Sept. 9. DermTech provides the only commercial-stage genomics-based non-invasive solution...

Motus GI Holdings

AGP ups Motus GI Holdings PT to $2.60 from $1.65

Alliance Global Partners raised its price target for Motus GI Holdings (NASDAQ:MOTS) to $2.60 from $1.65, “rolling our valuation multiple onto our newly introduced 2022 estimates and utilizing 50 million as our share...

Corbus Pharmaceuticals

HCW reduces Corbus Pharma PT to $6 from $24

H.C. Wainwright slashed the price target for Corbus Pharmaceuticals (NASDAQ:CRBP) to $6 from $24 but maintained its “buy” rating after the company’s Phase 3 RESOLVE-1 trial of lenabasum in cutaneous systemic sclerosis...

HCW starts Surface Oncology at buy; PT $11

H.C. Wainwright launched coverage of Surface Oncology (NASDAQ:SURF) with a “buy” rating and $11 price target. The stock closed at $6.40 on Sept. 3. Surface is developing cancer therapies targeting checkpoints that...

Alphatec Spine Logo

Cowen starts Alphatec Spine at OP; PT $12

Cowen launched coverage of Alphatec Spine (NASDAQ:ATEC) with an “outperform” rating and $12 price target. The stock closed at $6.09 on Sept. 2. Alphatec designs, develops, manufactures and markets surgical spine...

Constellation Logo

Brookline starts Constellation Pharma at buy; PT $33

Brookline Capital Markets initiated coverage of Constellation Pharmaceuticals (NASDAQ:CNST) with a “buy” rating and $33 price target. The stock closed at $21 on Sept 2. Constellation is using epigenetics to address...

Acasti Pharma

Echelon cuts Acasti Pharma to sell; PT to 15 cents

Echelon Wealth Partners downgraded Acasti Pharma (TSXV:ACST) to “sell” from “speculative buy” and slashed its price target to 15 cents (Canadian) from $1.40 after the company reported that its Phase 3 TRILOGY 2 trial...

Analysts start Acutus Medical at hold, buy, OP

Analysts for Canaccord Genuity, BTIG and William Blair launched coverage of Acutus Medical (NASDAQ:AFIB) with “hold”, “buy” and “outperform” ratings, respectively.  Acutus is a pure-play electrophysiology company...

Brookline Logo

Brookline starts Forte Biosciences at buy; PT $90

Brookline Capital Markets launched coverage of Forte Biosciences (NASDAQ:FBRX) with a “buy” rating and $90 price target. The stock closed at $26.69 on Aug. 27. Forte Biosciences is developing FB-401, a topical live...

HCW starts Personalis at buy; PT $30

H.C Wainwright launched coverage of Personalis (NASDAQ:PSNL) with a “buy” rating and $30 price target. The stock closed at $21.88 on Aug. 26. Personalis is a developer of next generation sequencing technologies and...

Onconova Logo

HCW cuts Onconova Therapeutics to neutral; removes PT

H.C. Wainwright downgraded Onconova Therapeutics (NASDAQ:ONTX) to “neutral” from “buy” without a price target after the company’s Phase 3 INSPIRE trial with rigosertib in high-risk myelodysplastic syndromesfailed on...

Brookline starts 9 Meters Biopharma at buy; PT $5

Brookline Capital Markets initiated coverage of 9 Meters Biopharma (NASDAQ:NMTR) with a “buy” rating and $5 price target. At midday on Aug. 20, the stock was quoted at 68 cents. 9 Meters is focused on two...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.